COMMUNIQUÉS West-GlobeNewswire
-
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026 -
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026 -
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026 -
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026 -
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
27/05/2026 -
L’Association canadienne de dermatologie, en partenariat avec Mélanome Canada, offrira des dépistages gratuits du cancer de la peau sur la Colline du Parlement
27/05/2026 -
Canadian Dermatology Association in Partnership with Melanoma Canada Offer Free Skin Cancer Screenings on Parliament Hill
27/05/2026 -
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
27/05/2026 -
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
27/05/2026 -
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
27/05/2026 -
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
27/05/2026 -
Satellos to Participate in Upcoming Investor Conferences
27/05/2026 -
Axsome Therapeutics to Participate in Upcoming Investor Conferences
27/05/2026 -
BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments
27/05/2026 -
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
27/05/2026 -
Invivyd to Participate in Upcoming Investor Events
27/05/2026 -
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
27/05/2026 -
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026 -
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Pages